Researchers at the Icahn School of Medicine at Mount Sinai reported preclinical data showing IL‑12–producing CAR T cells that target tumor‑associated macrophages (TAMs) remodel the tumor microenvironment and extend survival in aggressive metastatic ovarian and lung cancer mouse models. Instead of focusing on tumor antigens, the engineered CAR T cells deplete immunosuppressive macrophages and deliver IL‑12 to reactivate local immunity, enabling subsequent tumor elimination. The group published the work in Cancer Cell and positioned the approach as a broadly applicable strategy to overcome solid‑tumor resistance to cellular therapies. Translational steps will require safety profiling for myeloid targeting and IL‑12 delivery.